Effects of percutaneous estradiol–oral progesterone versus oral conjugated equine estrogens–medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women

In a prospective, randomized clinical study 77 women were assigned randomly to receive sequential hormone therapy with either conventional oral conjugated equine estrogens (0.625 mg) with the addition on 14 of the 28 days of oral medroxyprogesterone acetate (5 mg) or with oral micronized P (200 mg) on 14 of the 28 days of each cycle. Because oral conjugated equine estrogens–medroxyprogesterone acetate induced a highly significant increase in breast cell proliferation in contrast to percutaneous E2–oral P with a difference between therapies approaching significance, the former therapy has a marked impact on the breast whereas natural percutaneous E2–oral micronized P has not. (Fertil Steril® 2011;95:1188–91. ©2011 by American Society for Reproductive Medicine.)

Key Words: Percutaneous estradiol, micronized progesterone, HT, proliferation, bcl-2 protein, normal breast tissue

Postmenopausal hormone therapy (HT) has been associated with an increased risk for breast cancer. The risk with combined estrogen-progestogen therapy is greater than with estrogen alone (1–6). Hormone therapy is not a uniform concept, and various preparations, doses, and regimens of HT may have different effects (7). Although estrogen is a known mitogen in the breast, the effects of added progestogens may vary considerably (8–15), but proliferative responses are seen within 2 months (9–11). Synthetic progestogens may differ from natural P. In the French E3N cohort, women taking estrogen in combination with micronized P were found to have no increase in breast cancer risk in contrast to women taking estrogen in combination with synthetic progestogens (16, 17).

In this study we used core needle biopsy to evaluate breast cell proliferation in healthy postmenopausal women during two different types of sequential HTs: oral conjugated estrogens plus synthetic progestogen versus percutaneous E2 plus natural oral micronized P. A prospective randomized clinical study was performed at the Karolinska University Hospital, Stockholm, Sweden, between May 2006 and March 2008. Apparently healthy women, aged 44 to 66 years, postmenopausal for at least 12 months, nonsmokers, with normal mammogram results, and with a body mass index of 18 to 30 kg/m2, were recruited. Follicle-stimulating hormone levels at screening were >25 IU/L, and E2 levels <90 pmol/L. The washout period for previous HT users was 3 months.

Exclusion criteria were any breast disease, previous breast surgery, hepatic dysfunction, active gallbladder disease, or history of thromboembolic disease. Medication with sexual steroids, barbiturates, carbamazepines, phenytoin, glucocorticoids, rifampicin, cimetidine, diltiazem, erythromycin, ketoconazole, verapamil, and quinidine was not permitted.

The study was approved by the independent ethics committee IRB-2005/762-31 and the Swedish Medical Products Agency EU-2005/001016-51. All women gave their written informed consent.
Seventy-seven women were assigned randomly to receive sequential HT with two 28-day cycles of either oral 0.625 mg conjugated equine estrogens or 2.5 g 0.06% percutaneous E2 gel (1.5 mg E2), daily, with the addition of respectively 5 mg of oral medroxyprogesterone acetate (MPA) or 200 mg of oral P, daily, for the last 14 days of each cycle.

Two percutaneous stereotactic core needle biopsies were performed before treatment and during one of the last 3 days of the second 28-day treatment cycle, respectively, with the patient under local anesthesia on a prone table (Lorad, DSM, Danbury, CT) in the upper outer quadrant of the left breast. The biopsies were paraffin embedded and sectioned at 5 μm until dewaxed and immunostained.

Immunostained cells were quantified with use of cell counting of all available positive and negative cells and fields by two observers blinded to treatment with the Ki-67/MIB-1 monoclonal antibody (Bench Mark, Ventana Medical Systems, Illkirch Cedex, France) (18). The procedure uses an avidin-biotin peroxidase system in a Bench Mark staining module, which is a fully computerized system that performs deparaffinization, antigen retrieval, staining with amplification, and counterstaining in a standardized and reproducible fashion. Samples containing ≥50 breast epithelial cells were considered evaluable. Immunostaining for the anti-apoptotic protein bcl-2 was performed with use of the commercially available antibody bcl-2 clone 124 (nr 760-4246; Cell Marque Corp., Rocklin, CA) (19).

Circulating sex steroid levels and sex hormone-binding globulin before treatment and on one of the last 3 days of the second 28-day treatment cycle were quantified by routine hospital methods. Concentrations of free T were calculated as described earlier (20).

The detection limits and within- and between-assay coefficients of variation for T 0.1 nmol/L were 6% and 12%, for sex hormone-binding globulin 0.2 nmol/L 6.5% and 8.7%, for E2 Spectra 5 pmol/L 7.4% (Orion Diagnostica Oy, Espoo, Finland) and 10.3%, for E2 Immulite 55 pmol/L 9.3% (Diagnostic Products Corporation, Los Angeles, CA) and 10.6%, and for P 0.6 nmol/L 8.2% and 9.3%.

Differences between the two treatment groups were assessed with use of the Mann-Whitney test. For within-group changes the Wilcoxon signed-rank test was used. Correlations were assessed by Spearman’s rank correlation test. A P value < .05 was considered statistically significant.

In total, 99 women were tested for eligibility. Twenty-two women were excluded for not meeting the inclusion criteria. Seventy-seven women were assigned randomly. A total of 71 women, 37 receiving conjugated equine estrogens–MPA and 34 receiving E2–P, completed the study.

From the 71 women a total of 284 core needle biopsy specimens were collected. Forty of the 71 women (56%) had assessable samples at baseline, 53 of 71 (75%) at 2 months, and 35 of 71 (49%) both at baseline and after 2 months. There were no significant differences between treatment groups in mean age, body mass index,
parity, years since menopause, proportion of Ki-67–positive cells or bcl-2–positive cells, or serum hormone levels at baseline.

After 2 months of treatment, conventional HT, that is, conjugated equine estrogens–MPA orally, increased proliferation more than treatment with natural percutaneous E$_2$ in combination with oral P, at borderline significance ($P=0.05$). The conventional therapy induced a highly significant increase in proliferation from mean 1%, median 0.6%, and range 0% to 4% at baseline to mean 10.0%, median 2.6%, and range 0% to 56% of proliferating normal breast epithelial cells after 2 months of treatment ($P=0.003$). In contrast, treatment with percutaneous E$_2$–oral P did not significantly increase proliferation (mean 3.1%, median 1.4%, range 0% to 21.5% at baseline vs. mean 5.8%, median 1.8%, and range 0% to 39% at 2 months) (Fig. 1). This proliferative response of sequential conjugated equine estrogens–MPA is similar to that of conventional continuous combined treatment found in earlier studies (12, 15, 21, 22) whereas the natural E$_2$–P therapy did not increase breast cell proliferation significantly in conformity with previous findings (23). Increased proliferation during HT must be regarded as an unwanted potentially hazardous side effect whereas increased apoptosis reasonably is beneficial. The proportion of bcl-2–positive cells was numerically down-regulated during both therapies approaching significance ($P=0.06$) for the natural regimen from mean 49%, median 50%, and range 0% to 100% before treatment to mean 26%, median 40%, range 0% to 80% at 2 months. The conjugated equine estrogens–MPA group values for bcl-2 were mean 46%, median 60%, range 0% to 90% (baseline) versus mean 27%, median 20%, range 0% to 80% (2 months) without between-groups difference. Down-regulation became significant for the total material of both treatments ($P=0.01$), thus facilitating apoptosis.

In this study conjugated equine estrogens plus MPA orally were found to increase proliferation more than treatment with natural percutaneous E$_2$ in combination with oral P only at borderline significance. The power calculations before the study were based on the assumption of a yield of at least 55% assessable samples both before and after treatment as found by us earlier with fine-needle aspiration biopsies (12, 21, 24), resulting in the need for 70 women to fulfill the study. However, with core needle biopsy, unexpectedly, only 49% of the women had assessable breast epithelium in biopsies both before and after 2 months of treatment.

Although progestogens have been identified as a potential risk factor, there are indications of important differences between preparations. In the French E3N cohort there was an absence of breast cancer risk increase for women taking estrogen in combination with natural P for at least 5 years of treatment (17, 25). This is in line with the indication in the current study of a higher proliferative activity in the breast imposed by oral conjugated equine estrogens–MPA versus percutaneous E$_2$–micronized P orally, maintaining an E$_2$ dose of 1.5 mg daily, which is needed by many women at least in an initial phase of postmenopausal symptoms.

Not only natural P but also E$_2$ given through the transdermal route may add to the less-adverse effects on the breast compared with the conventional oral therapy. In the large General Practitioners Research Database no increase in risk for breast cancer was observed when opposed estrogens were given transdermally in contrast to estrogens given orally (26–28).

Although we now have found it clearly less proliferative than MPA, it is important to stress that P was not found to be antiproliferative in normal breast tissue (9). Furthermore, both MPA and P have been found to reactivate stem cells with potential for malignancy, in vitro, but the clinical implications of this finding for women are not elucidated (29). Recently we reported that so far the only antiproliferative drug in normal breast tissue in vivo is the anti-P mifepristone, which significantly reduced breast cell proliferation in premenopausal women (30).

The long-term safety of combined HT especially in the breast has been discussed vividly over the past decades. The need is strong to define treatment regimens and alternatives for postmenopausal women that have minimal effects on the breast but still allow effective symptom relief.

The study does not answer whether the estrogenic or progestogenic component of HT, or a synergy between both, gives the more beneficial effect with use of natural treatment. However, for millions of women with severe climacteric symptoms, we need to find and evaluate efficient HTs with as low impact on the breast as possible. The findings of this study suggest that 2 months of treatment with percutaneous E$_2$ in combination with 14 of 28 days of micronized P has less-adverse effects on normal human breast proliferation in vivo, and it also seems to facilitate apoptosis.

Acknowledgments: Technical assistance was provided by Birgitta Byström, Berit Legerstam, Torsten Hägerström, Eva Andersson, Siv Rödin, and Lotta Blomberg.

REFERENCES


